C
Concepción Boqué
Researcher at University of Barcelona
Publications - 42
Citations - 3434
Concepción Boqué is an academic researcher from University of Barcelona. The author has contributed to research in topics: Myeloid leukemia & Dasatinib. The author has an hindex of 15, co-authored 37 publications receiving 3025 citations.
Papers
More filters
Journal ArticleDOI
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian,Neil P. Shah,Andreas Hochhaus,Jorge E. Cortes,Sandip Shah,Manuel Ayala,Beatriz Moiraghi,Zhixiang Shen,Jiri Mayer,Ricardo Pasquini,Hirohisa Nakamae,Françoise Huguet,Concepción Boqué,Charles Chuah,Eric Bleickardt,M. Brigid Bradley-Garelik,Chao Zhu,Ted Szatrowski,David Shapiro,Michele Baccarani +19 more
TL;DR: Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.
Journal ArticleDOI
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes,Giuseppe Saglio,Hagop M Kantarjian,Michele Baccarani,Jiří Mayer,Concepción Boqué,Neil P. Shah,Charles Chuah,Luis Casanova,Brigid Bradley-Garelik,George Manos,Andreas Hochhaus +11 more
TL;DR: These final results from the DASISION trial continue to support dasatinib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP.
Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Naïve chronic myeloid leukemia patients trial
Hagop M. Kantarjian,Jorge E. Cortes,George Manos,Neil P. Shah,Jiří Mayer,Andreas Hochhaus,Michele Baccarani,Brigid Bradley Garelik,Charles Chuah,Concepción Boqué,Giuseppe Saglio,Luis Casanova Márquez +11 more
Journal ArticleDOI
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias J. Jabbour,Hagop M. Kantarjian,Giuseppe Saglio,Juan Luis Steegmann,Neil P. Shah,Concepción Boqué,Charles Chuah,Carolina Pavlovsky,Jiri Mayer,Jorge E. Cortes,Michele Baccarani,Dong-Wook Kim,M. Brigid Bradley-Garelik,Hesham Mohamed,Mark Wildgust,Andreas Hochhaus +15 more
TL;DR: The achievement of an early molecular response was predictive of improved progression-free survival and overall survival, supporting new milestones for optimal response in patients with early CML-CP treated with tyrosine kinase inhibitors.
Journal ArticleDOI
Cadherin-13, a Mediator of Calcium-Dependent Cell-Cell Adhesion, Is Silenced by Methylation in Chronic Myeloid Leukemia and Correlates With Pretreatment Risk Profile and Cytogenetic Response to Interferon Alfa
Jose Roman-Gomez,Juan A. Castillejo,Antonio M. Jimenez,Francisco Cervantes,Concepción Boqué,Lourdes Hermosín,Angel Leon,Albert Grañena,Dolors Colomer,Anabel Heiniger,Antoni Torres +10 more
TL;DR: The data indicate that the silencing of CDH13 expression by aberrant promoter methylation occurs at an early stage in CML pathogenesis and probably influences the clinical behavior of the disease.